Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737632 | 0.88 | HPGD (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22737529 | 0.88 | HPGD (0.43) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL25475559 | 0.85 | NR1H2 (0.46) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22737324 | 0.85 | HPGD (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22737641 | 0.85 | HPGD (0.42) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22737716 | 0.83 | OPRM1 (0.41) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL29134829 | 0.82 | NR1H2 (0.48) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL29134416 | 0.82 | NR1H2 (0.48) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL24033163 | 0.82 | NR1H2 (0.48) | NR1H2MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2675192 | 0.81 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | NR1H2 1427/4885MEN1 1411/4885ALDH1A1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.